# Compass Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Compass Therapeutics, Inc.).

## Overview

Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies. Its pipeline centers on bispecific and other proprietary antibodies designed to disrupt angiogenesis and tumor biology, with lead programs including tovecimig, CTX-471, CTX-8371, and CTX-10726.

## Products & services

• Tovecimig (CTX-009) bispecific antibody for oncology
• CTX-471 antibody program targeting immune-oncology pathways
• CTX-8371 antibody program in the cancer pipeline
• CTX-10726 preclinical/IND-enabling oncology candidate
• StitchMabsTM antibody engineering platform
• Out-licensed licensing and collaboration rights

- **Clinical-stage oncology programs** (85%) — Lead and follow-on antibody candidates being advanced through clinical and IND-enabling development.
- **Platform technology** (10%) — StitchMabsTM and related antibody discovery/engineering capabilities used to create bispecifics.
- **Licensing and collaboration revenue** (5%) — Milestones and other payments from partners for licensed product rights and development progress.

- Tovecimig (CTX-009) bispecific antibody for oncology
- CTX-471 antibody program targeting immune-oncology pathways
- CTX-8371 antibody program in the cancer pipeline
- CTX-10726 preclinical/IND-enabling oncology candidate
- StitchMabsTM antibody engineering platform
- Out-licensed licensing and collaboration rights

## Customers

Compass Therapeutics does not yet sell approved products; its current economic counterparties are licensing partners, contract manufacturers, and clinical research vendors. If approved, its end customers would be physicians, hospitals, and third-party payors that influence adoption and reimbursement of oncology therapies.

- **Licensing and collaboration partners** (primary) — Biopharma partners that pay milestones or royalties for rights to selected programs or geographies.
- **Clinical trial ecosystem** (primary) — Hospitals, investigators, CROs, and vendors that support development of product candidates.
- **Future oncology prescribers** (secondary) — Physicians and cancer centers that would use approved products if the pipeline reaches market.
- **Third-party payors** (secondary) — Insurers and reimbursement bodies that would influence uptake and net access after approval.

- Pharma/biotech partners that license regional or program rights
- Clinical trial sites and investigators running oncology studies
- Contract manufacturers supplying clinical and future commercial material
- Physicians and hospitals that would prescribe approved therapies
- Third-party payors that would determine reimbursement access

## Geography

Compass Therapeutics is headquartered in Boston, Massachusetts and operates as a U.S.-based clinical-stage company with worldwide rights to most of its programs. The company relies on third-party manufacturers and research partners, and it has disclosed a China-linked milestone from Elpiscience tied to a Phase 1 trial, showing that development and partnering can extend beyond the U.S.

- Headquartered in Boston, Massachusetts
- Clinical development and corporate functions are U.S.-based
- Worldwide rights to most product candidates support global partnering
- China milestone revenue came from Elpiscience for Phase 1 completion
- Third-party manufacturing and trials may occur in multiple countries

## Strategy

The company is focused on advancing its antibody pipeline through clinical development while preserving optionality to partner selected rights by geography or program. Management also emphasizes capital discipline, noting that current cash is expected to fund operations into 2028, but additional financing or strategic transactions may still be needed to support development and eventual commercialization.

- **Advance the clinical pipeline** (short-term) — Clinical data and regulatory progress are the main value drivers for a pre-revenue biotech.
- **Maintain partnering optionality** (medium-term) — Regional or program-level deals can fund development and reduce capital burden.
- **Extend cash runway** (short-term) — The company expects to need substantial additional funding before product sales.

- Advance tovecimig and other oncology candidates through clinical stages
- Use the StitchMabs platform to generate differentiated antibody assets
- Partner selected geographies or programs to monetize non-core rights
- Rely on third-party manufacturers and research vendors to stay asset-light
- Preserve cash runway while preparing for future commercialization choices

## Risks

Compass Therapeutics is a pre-commercial biotech with no approved products, so its value depends on successful clinical development, regulatory clearance, and eventual market adoption. It also depends heavily on third parties for trials and manufacturing, and it faces typical oncology-biotech risks such as capital needs, intellectual property competition, and cybersecurity exposure.

- **No products approved for commercial sale** [critical] — The company has a limited operating history and depends on pipeline success to create revenue.
- **Need for additional capital** [high] — R&D spending exceeds revenue and the company may need equity, debt, or partnerships to fund operations.
- **Third-party trial and manufacturing dependence** [high] — The company relies on CROs and contract manufacturers for clinical studies and supply.
- **Intellectual property competition** [medium] — Biotech competitors and larger pharma companies may develop similar oncology assets or challenge IP.
- **Cybersecurity and data privacy** [medium] — Research data, IP, and personal information are stored digitally and may be targeted or disrupted.

- No approved products means no commercial revenue base
- Clinical failure or delays could impair pipeline value
- Third-party CRO/manufacturer execution risk can disrupt timelines
- Additional financing may be needed before profitability
- Patent and IP competition is intense in oncology biologics
- Cybersecurity or data breaches could expose sensitive research data

## Accounting

The most important accounting judgments are in R&D expense recognition, where external development costs are expensed as incurred and vendor progress estimates drive accruals or prepaids. Investors should also watch stock-based compensation, lease accounting for Boston office/lab space, and milestone-based licensing revenue, which can create lumpy quarterly results.

- **Research and development expense accruals** — Can shift expense timing between periods
- **Milestone-based licensing revenue** — Can materially affect quarterly comparability
- **Stock-based compensation** — Affects operating loss and non-cash expense profile
- **Operating lease commitments** — Affects liquidity analysis and future cash outflows

- R&D is expensed as incurred, making spend timing important
- Vendor accruals depend on management estimates of work completed
- Licensing milestones can create uneven revenue recognition
- Stock-based compensation is material in both R&D and G&A
- Operating lease commitments affect cash needs and balance sheet disclosures

---

*Last updated: 2026-04-28T19:58:46.934353+00:00*